News 2n In the News 3rd ALS Drug Discovery Summit May 20, 2024 Read More New article in npj Parkinson’s Disease Jan 24, 2023 Read More 2N Pharma and our CSO mentioned in the Washington Post Dec 01, 2022 Read More Meet 2N Pharma at the Anglonordic Life Science Conference May 03, 2022 Read More US Department of Defense awarded 2N Pharma a grant of 944.000 USD Apr 12, 2022 Read More DKBIO 2022 brings together Scandinavian bioscience start-ups with investors Apr 05, 2022 Read More Neurodegeneration: unique and innovative approach to develop a cure Mar 24, 2022 Read More Women in STEM: this is why a career in science is so fascinating Feb 11, 2022 Read More 2N Pharma will be presenting at BioSeed 2022 Jan 19, 2022 Read More CEO Preben Bruun-Nyzell participates in BIO Partnering at JPM Jan 05, 2022 Read More Season’s Greetings from 2N Pharma Dec 23, 2021 Read More Virtual 32nd International Symposium on ALS/MND Dec 12, 2021 Read More 2N Pharma Announces Appointment of Alex Leech as Chair of the Board of Directors and John Kemp as Non-Executive Director Jun 23, 2021 Read More 2N Pharma’s ALS Clinical Development Plan completed May 06, 2021 Read More 2N Pharma receives grant from Innovation Fund Denmark May 05, 2021 Read More 2N Pharma’s ground-breaking approach to treating neurological diseases recognised in Nature Journal Apr 30, 2021 Read More AI speeds up the R&D for ALS treatment Apr 21, 2021 Read More The 2N Pharma Team – Michael Sloth Trabjerg Mar 16, 2021 Read More ALS – Can ‘Mitometin’ finally be a successful treatment for this rare disease? Feb 28, 2021 Read More Choosing a Career in Science? Feb 24, 2021 Read More BII awards 14 million EUR to startups and research projects Oct 27, 2020 Read More ALS start-up funded by BII Oct 27, 2020 Read More Ground-breaking ALS start-up accepted into the Creation House program of BioInnovation Institute (BII), securing funding of EUR 1.3 million Oct 27, 2020 Read More ALS In the News Check out all the latest worldwide news about ALS ALS Articles Media Contact
2N Pharma Announces Appointment of Alex Leech as Chair of the Board of Directors and John Kemp as Non-Executive Director Jun 23, 2021 Read More
2N Pharma’s ground-breaking approach to treating neurological diseases recognised in Nature Journal Apr 30, 2021 Read More
ALS – Can ‘Mitometin’ finally be a successful treatment for this rare disease? Feb 28, 2021 Read More
Ground-breaking ALS start-up accepted into the Creation House program of BioInnovation Institute (BII), securing funding of EUR 1.3 million Oct 27, 2020 Read More
